United Therapeutics Corp (NASDAQ: UTHR) recently saw significant insider activity as Chief Financial Officer and Treasurer James Edgemond executed several transactions involving the company's common stock. On April 27, 2026, Mr. Edgemond sold shares totaling roughly $5.69 million. These activities were not spontaneous; they were carried out according to a Rule 10b5-1 trading plan that was put in place on October 31, 2025.
Transaction Breakdown
The movement of shares involved both the exercise of options and subsequent liquidations. Specifically, Mr. Edgemond acquired 10,000 shares of common stock by exercising options at a rate of $135.42 per share, an amount totaling $1,354,199. These specific options had an exercise date of March 15, 2023, and are set to expire on March 15, 2027. Following this acquisition, the entirety of those 10,000 shares was sold through a series of trades. The execution prices for these sales ranged from $565.22 to $572.415 per share, bringing the total value of the disposals to $5,688,318.
Following these completed transactions, Mr. Edgemond retains a direct holding of 18,876 shares of United Therapeutics common stock. Furthermore, he maintains a position in derivative shares consisting of 52,500 stock options.
Market Context and Valuation
The timing of these sales occurs amidst a period of notable stock performance for the biotech firm. Over the last year, United Therapeutics has seen a 91% return on its stock, which is currently trading at $569.26. Despite this upward momentum, certain analyses suggest caution; current valuations indicate the stock may be overvalued relative to its Fair Value, particularly as it trades near its 52-week high of $607.89.
Operational and Clinical Developments
United Therapeutics has been involved in several recent regulatory and scientific milestones. The U.S. Food and Drug Administration (FDA) recently granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver device designed by Miromatrix Medical Inc. This device is intended to offer temporary liver support for patients suffering from acute liver failure. Additionally, the company is preparing for a significant presence at the upcoming International Society for Heart and Lung Transplantation Annual Meeting, where it plans to present 11 different data presentations focusing on studies related to arterial hypertension and pulmonary hypertension.
Analyst Outlook
The financial community has shown varying levels of optimism regarding the company's future. Raymond James initiated coverage with an Outperform rating and a $700 price target, driven by expectations that Tyvaso could achieve peak sales exceeding $5 billion for idiopathic pulmonary fibrosis. Similarly, H.C. Wainwright raised its price target to $660, noting strong data from the TETON-1 trial for Tyvaso. BofA Securities also increased its target to $626, citing positive Phase 3 trial results for the same medication. These projections highlight a collective focus on the commercial potential of Tyvaso in treating idiopathic pulmonary fibrosis.